1 Min Read
March 9 (Reuters) - Beigene Ltd:
* Beigene announces initiation of pivotal study in China with BTK inhibitor BGB-3111 in patients with relapsed or refractory CLL/SLL Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.